{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:26:20Z","timestamp":1787811980795,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["667403"],"award-info":[{"award-number":["667403"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["965193"],"award-info":[{"award-number":["965193"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["325956"],"award-info":[{"award-number":["325956"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.tranon.2023.101814","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T08:22:38Z","timestamp":1698913358000},"page":"101814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence"],"prefix":"10.1016","volume":"39","author":[{"given":"Giovanni","family":"Marchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-5419","authenticated-orcid":false,"given":"Anna","family":"Rajavuori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-4416","authenticated-orcid":false,"given":"Mai T.N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Huhtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinikka","family":"Oksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7749-2694","authenticated-orcid":false,"given":"Sampsa","family":"Hautaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-7225","authenticated-orcid":false,"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-2736","authenticated-orcid":false,"given":"Jaana","family":"Oikkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2023.101814_bib0001","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 Cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.tranon.2023.101814_bib0003","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian cancer prevention and screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.tranon.2023.101814_bib0004","first-page":"284","article-title":"Ovarian cancer statistics","volume":"68","author":"Torre","year":"2018","journal-title":"CA. Cancer J. Clin."},{"issue":"10177","key":"10.1016\/j.tranon.2023.101814_bib0005","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.tranon.2023.101814_bib0006","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","article-title":"Diagnosis and Treatment of Ovarian Cancer","volume":"32","author":"Orr","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"20","key":"10.1016\/j.tranon.2023.101814_bib0007","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.tranon.2023.101814_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijgo.2009.08.034","article-title":"Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer","volume":"108","author":"Schorge","year":"2010","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.tranon.2023.101814_bib0009","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2023.101814_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2023.101814_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLOS Med"},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0012","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"issue":"9332","key":"10.1016\/j.tranon.2023.101814_bib0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tranon.2023.101814_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"Npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2023.101814_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12885-015-1077-4","article-title":"Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing","volume":"15","author":"Lee","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0016","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3892\/etm.2022.11479","article-title":"Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer","volume":"24","author":"Jie","year":"2022","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00343","article-title":"Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer","author":"Oikkonen","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tranon.2023.101814_bib0018","unstructured":"Turku University Hospital, Integration of Multiple Data Levels to Improve Diagnosis, Predict Treatment Response and Suggest Targets to Overcome Therapy Resistance in High-grade Serous Ovarian Cancer, Clinicaltrials.Gov, 2022."},{"key":"10.1016\/j.tranon.2023.101814_bib0019","article-title":"New algorithm for analysis of tumor DNA reveals mutations previously not found","year":"2020","journal-title":"Hartwig Med. Found."},{"issue":"19","key":"10.1016\/j.tranon.2023.101814_bib0020","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1093\/bioinformatics\/btz133","article-title":"Anduril 2: upgraded large-scale data integration framework","volume":"35","author":"Cervera","year":"2019","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.tranon.2023.101814_bib0021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"D1","key":"10.1016\/j.tranon.2023.101814_bib0022","doi-asserted-by":"crossref","first-page":"D886","DOI":"10.1093\/nar\/gky1016","article-title":"CADD: predicting the deleteriousness of variants throughout the human genome","volume":"47","author":"Rentzsch","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.tranon.2023.101814_bib0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto Encyclopedia of Genes and Genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.tranon.2023.101814_bib0024","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/nprot.2016.117","article-title":"Analyzing and interpreting genome data at the network level with ConsensusPathDB","volume":"11","author":"Herwig","year":"2016","journal-title":"Nat. Protoc."},{"issue":"7","key":"10.1016\/j.tranon.2023.101814_bib0025","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41591-020-0969-2","article-title":"Support systems to guide clinical decision-making in precision oncology: the cancer core europe molecular tumor board portal","volume":"26","author":"Tamborero","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.tranon.2023.101814_bib0026","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1101\/gr.230219.117","article-title":"In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors","volume":"28","author":"Boot","year":"2018","journal-title":"Genome Res."},{"issue":"9","key":"10.1016\/j.tranon.2023.101814_bib0027","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tranon.2023.101814_bib0029","article-title":"Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients","author":"Lahtinen","year":"2022","journal-title":"Cancer Biol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4143\/crt.2019.700","article-title":"Clinical implications of circulating tumor dna from ascites and serial plasma in ovarian cancer","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.tranon.2023.101814_bib0031","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0032","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ygyno.2021.04.020","article-title":"Epithelial ovarian cancer and the use of circulating tumor DNA: a systematic review","volume":"161","author":"Thusgaard","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101814_bib0033","first-page":"109","article-title":"Differences in genomic profile of high-grade urothelial carcinoma according to tumor location","volume":"40","author":"Park","year":"2022","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"19","key":"10.1016\/j.tranon.2023.101814_bib0034","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1158\/1078-0432.CCR-21-1221","article-title":"Location of gastrointestinal stromal tumor (GIST) in the stomach predicts tumor mutation profile and drug sensitivity","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2023.101814_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00535","article-title":"Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer","author":"Bando","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2023.101814_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS ONE"},{"issue":"7969","key":"10.1016\/j.tranon.2023.101814_bib0037","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","article-title":"Practical recommendations for using ctDNA in clinical decision making","volume":"619","author":"Cohen","year":"2023","journal-title":"Nature"},{"issue":"15_suppl","key":"10.1016\/j.tranon.2023.101814_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.5549","article-title":"Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial","volume":"34","author":"Piskorz","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323002000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323002000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:28:34Z","timestamp":1761845314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523323002000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"alternative-id":["S1936523323002000"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101814","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101814"}}